---
title: tumor organoids
description: Read this fact sheet on the application of tumor organoids in accelerating the drug development pipeline by reducing drug attrition rates and better predicting patient response.
image: https://resources.huborganoids.nl/hubfs/Tumor%20organoid%20flyer.jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

FACT SHEET

# Tumor organoids

Patient-derived models for the next-gen drug discovery and development

## Reduce oncology drug attrition rates

### Predict patient response before moving your drug to the clinic

HUB Organoids are unique patient-derived *in vitro* models developed directly from patient biopsies or resections. Our living tumor biobank includes:

- genetically stable organoid models
- a wide range of carcinoma indications
- matched primary tumor and healthy tissue-derived organoids
- organoids derived from both primary and metastatic lesions

Using [HUB´s drug screening platform](https://huborganoids.nl/services/hub-organoid-clinical-trial-in-a-dish), clinically-relevant data can be generated that allows you to identify new targets, refine your drug combination strategies, or stratify your patient population with confidence.

### Download our fact sheet

![patient population](https://resources.huborganoids.nl/hubfs/graphics%20500x500%20px%20(4).png "patient population")

### Identify responders and non-responders

Prospectively identify your target patient population and investigate the mechanism of response in patients.

![drugs](https://resources.huborganoids.nl/hubfs/graphics%20500x500%20px%20(5).png "drugs")

### Test combination strategies

Identify the most promising combo startegy with the only easily scalable patient-derived *in vitro* system. 

![DNA](https://resources.huborganoids.nl/hubfs/graphics%20500x500%20px%20(11).png "DNA")

### Discover predictive biomarkers

Predict therapeutic outcome using models that recapitulate original patient pathophysiology and preserve patient- and cancer-specific mutations.

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*